253 related articles for article (PubMed ID: 22510516)
21. HSP90 expression is associated with outcome in pulmonary carcinoid tumor patients.
Niinimäki J; Sihto H; Arola J; Vesterinen T
Transl Lung Cancer Res; 2023 Sep; 12(9):1876-1886. PubMed ID: 37854156
[TBL] [Abstract][Full Text] [Related]
22. Revealing Propolis Potential Activity on Inhibiting Estrogen Receptor and Heat Shock Protein 90 Overexpressed in Breast Cancer by Bioinformatics Approaches.
Simanjuntak MV; Jauhar MM; Syaifie PH; Arda AG; Mardliyati E; Shalannanda W; Hermanto BR; Anshori I
Bioinform Biol Insights; 2024; 18():11779322231224187. PubMed ID: 38274992
[TBL] [Abstract][Full Text] [Related]
23. Association Analysis of Somatic Copy Number Alteration Burden With Breast Cancer Survival.
Zhang L; Feizi N; Chi C; Hu P
Front Genet; 2018; 9():421. PubMed ID: 30337938
[TBL] [Abstract][Full Text] [Related]
24. The Role of Transcription Factors in the Loss of Inter-Chromosomal Co-Expression for Breast Cancer Subtypes.
Trujillo-Ortíz R; Espinal-Enríquez J; Hernández-Lemus E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139393
[TBL] [Abstract][Full Text] [Related]
25. Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity.
Houlahan KE; Khan A; Greenwald NF; West RB; Angelo M; Curtis C
bioRxiv; 2023 Mar; ():. PubMed ID: 36993286
[TBL] [Abstract][Full Text] [Related]
26. High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia.
Lin CH; Huang RY; Lu TP; Kuo KT; Lo KY; Chen CH; Chen IC; Lu YS; Chuang EY; Thiery JP; Huang CS; Cheng AL
NPJ Breast Cancer; 2021 Jul; 7(1):88. PubMed ID: 34226567
[TBL] [Abstract][Full Text] [Related]
27. Distinct Microbial Signatures Associated With Different Breast Cancer Types.
Banerjee S; Tian T; Wei Z; Shih N; Feldman MD; Peck KN; DeMichele AM; Alwine JC; Robertson ES
Front Microbiol; 2018; 9():951. PubMed ID: 29867857
[TBL] [Abstract][Full Text] [Related]
28. Potential use of heat shock protein 90 as a biomarker for the diagnosis of human diseases.
Rivas-Macho A; Romeo MV; Rackles E; Olabarria G; Falcon-Perez JM; Berganza-Granda J; Cortajarena AL; Goñi-de-Cerio F
Expert Rev Mol Diagn; 2023; 23(10):875-884. PubMed ID: 37577928
[TBL] [Abstract][Full Text] [Related]
29. FXYD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas.
Raman P; Purwin T; Pestell R; Tozeren A
Cancer Inform; 2015; 14():113-9. PubMed ID: 26494976
[TBL] [Abstract][Full Text] [Related]
30. Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer.
Margolin AA; Bilal E; Huang E; Norman TC; Ottestad L; Mecham BH; Sauerwine B; Kellen MR; Mangravite LM; Furia MD; Vollan HK; Rueda OM; Guinney J; Deflaux NA; Hoff B; Schildwachter X; Russnes HG; Park D; Vang VO; Pirtle T; Youseff L; Citro C; Curtis C; Kristensen VN; Hellerstein J; Friend SH; Stolovitzky G; Aparicio S; Caldas C; Børresen-Dale AL
Sci Transl Med; 2013 Apr; 5(181):181re1. PubMed ID: 23596205
[TBL] [Abstract][Full Text] [Related]
31. Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer.
Larsson C; Ehinger A; Winslow S; Leandersson K; Klintman M; Dahl L; Vallon-Christersson J; Häkkinen J; Hegardt C; Manjer J; Saal L; Rydén L; Malmberg M; Borg Å; Loman N
NPJ Breast Cancer; 2020; 6():28. PubMed ID: 32656317
[TBL] [Abstract][Full Text] [Related]
32. Novel HER-2 Targeted Therapies in Breast Cancer.
Fernandes CL; Silva DJ; Mesquita A
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201515
[TBL] [Abstract][Full Text] [Related]
33. Is STARD3 A New Biomarker for Breast Cancer?
Korucu AN; Inandiklioglu N
Eur J Breast Health; 2024 Apr; 20(2):89-93. PubMed ID: 38571685
[TBL] [Abstract][Full Text] [Related]
34. The therapeutic target Hsp90 and cancer hallmarks.
Miyata Y; Nakamoto H; Neckers L
Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
[TBL] [Abstract][Full Text] [Related]
35. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
[TBL] [Abstract][Full Text] [Related]
36. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
[TBL] [Abstract][Full Text] [Related]
37. Heat Shock Protein 90 Family Isoforms as Prognostic Biomarkers and Their Correlations with Immune Infiltration in Breast Cancer.
Lin T; Qiu Y; Peng W; Peng L
Biomed Res Int; 2020; 2020():2148253. PubMed ID: 33145341
[TBL] [Abstract][Full Text] [Related]
38. Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach.
Chatterjee S; Burns TF
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914774
[TBL] [Abstract][Full Text] [Related]
39. HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation.
Kijima T; Prince TL; Tigue ML; Yim KH; Schwartz H; Beebe K; Lee S; Budzynski MA; Williams H; Trepel JB; Sistonen L; Calderwood S; Neckers L
Sci Rep; 2018 May; 8(1):6976. PubMed ID: 29725069
[TBL] [Abstract][Full Text] [Related]
40. HSP90AB1: Helping the good and the bad.
Haase M; Fitze G
Gene; 2016 Jan; 575(2 Pt 1):171-86. PubMed ID: 26358502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
